Live·Open questions in longevity research
All news
Clinical trialsLongevity researchTherapeutics

The VITAL-H trial protocol now includes two drugs instead of three: 1200 healthy adults aged 60–75 will take a diabetes drug, weight-loss pills or placebo for three years, with success measured by tests of balance, walking and rising from a chair

10 November 2026· 261110009

The VITAL-H trial protocol now includes two drugs instead of three: 1200 healthy adults aged 60–75 will take a diabetes drug, weight-loss pills or placebo for three years, with success measured by tests of balance, walking and rising from a chair

On November 6, the clinical trial registry ClinicalTrials.gov published the VITAL-H protocol. The University of Texas at San Antonio is conducting the trial under a contract worth up to 38 million dollars with ARPA-H, a US federal agency that funds high-risk medical research. The estimated start date is January 2027, with primary data collection expected to end in December 2030.

The trial will test whether two drugs approved by the FDA for other uses slow age-related functional decline. Participants will be randomly assigned to three groups, and each will take two tablets daily for 36 months: dapagliflozin (a drug for diabetes, heart failure and kidney disease) plus placebo, oral semaglutide (the active ingredient in Wegovy) plus placebo, or two placebo tablets. This will keep everyone unaware of who receives which treatment. The semaglutide dose will increase from 1.5 to 4 mg as tolerated. According to the FDA prescribing information for Wegovy tablets, 4 mg is the second dose step, while the maintenance dose for weight loss is 25 mg.

In March, the university described a different plan: 726 people in their sixties, with three drugs compared against placebo across four groups. The third drug was rapamycin, which extended lifespan in mice. In February, ARPA-H described the trial as phase three, the final testing stage before approval; the protocol lists the earlier phase 2b. The current plan calls for 1200 participants aged 60–75 and three groups, with rapamycin absent from the drug list.

The ARPA-H program that includes VITAL-H is seeking measures that can reveal a drug's effects within one to three years: waiting for disease or disability to develop would take decades. VITAL-H's primary outcome is SPPB, a short battery of physical performance tests: holding three balance positions for up to ten seconds each, walking four meters and rising from a chair five times. The total score ranges from 0 to 12. In a meta-analysis of 17 studies (16 534 people, with a mean age of 76), those scoring 0–3 had 3.25 times the odds of death compared with those scoring 10–12. The authors proposed using SPPB in trials in place of mortality.

In March, trial leader Elena Volpi said: “We want the FDA to recognize intrinsic capacity as a meaningful regulatory endpoint.” Intrinsic capacity is a WHO concept encompassing all of a person's physical and mental abilities. The protocol lists the overall assessment of intrinsic capacity as an exploratory outcome, while the primary and secondary outcomes measure individual domains: locomotion (SPPB) and “vitality” (peak oxygen consumption on a stationary bicycle).

A working group convened by ARPA-H recommended a similar approach in its May 18 document for the FDA: in many early trials, measures of individual domains should serve as primary outcomes, while the overall assessment should be a secondary or exploratory outcome, to establish whether it changes during the trial and predicts future health. For locomotion, the group names SPPB, ideally with continuous scoring, as specified in the protocol. People with high physical performance can reach the ceiling of the conventional scale; the group considers continuous scoring more sensitive to change. In a Japanese study, 78.7% of 4328 community-dwelling older adults achieved the maximum score of 12. VITAL-H will also enroll healthy, community-dwelling adults aged 60–75, without diabetes, a history of heart attack or stroke, or heart failure.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#vital-h#dapagliflozin#semaglutide#healthspan#sppb#intrinsic-capacity